DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering May 8, 2019
DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference May 6, 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board Apr 4, 2019
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083 Apr 3, 2019
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM Feb 20, 2019
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting Nov 20, 2018
